The Medicines Co boosts hospital presence with Incline purchase, Recothrom deal
This article was originally published in Scrip
The Medicines Company will make an initial investment of $300 million to expand its hospital presence with the $185 million purchase of Incline Therapeutics and its Ionsys system for the short-term management of acute post-operative pain, as well as $115 million in collaboration and option fees for a two-year exclusive global license to market the topical hemostat Recothrom from Bristol-Myers Squibb.
You may also be interested in...
Five funds raised more than $1bn to back biotech firms; Arcus leads recent VC rounds with $107m GV-backed Series C; Celgene, Valeant sell notes to retire debt; and Alnylam cashes in on investor goodwill.
The GLP-1/GIP agonist tirzepatide is a key addition to Lilly’s commercial portfolio as the company leans on new products to deliver on volume-driven growth through the current decade.
The leader in inflammatory bowel disease via Humira, AbbVie awaits a US FDA decision in June for Skyrizi in Crohn’s disease and plans to add a Crohn’s indication to Rinvoq’s ulcerative colitis approval.